Printer Friendly

HARRIER ESTABLISHES BIOCHEMICAL SUBSIDIARY

 HARRIER ESTABLISHES BIOCHEMICAL SUBSIDIARY
 LOS ANGELES, Nov. 10 /PRNewswire/ -- Harrier, Inc. (NASDAQ: HARE)


said today that it will be transferring its biochemical assets and operations to a new subsidiary, the GlycoBiology Company Inc. (Delaware), which will develop, test and license patentable pharmaceuticals and chemical compounds resulting from Harrier's proprietary glycosylation processes.
 Kevin DeVito, Harrier president, said the move was being made to bring greater focus to its biochemical development activity in anticipation of consulting, financing and management agreements expected to be concluded before the end of the year.
 The strategy of the GlycoBiology Company is to utilize proprietary glycosylation technologies to enhance properties of existing pharmaceutical products and to develop pro-drugs. Initially, the company intends to evaluate its glycosylation technologies, utilizing readily available sugars, to improve products in the fields of anti-bacterial and anti-neoplastic agents. Envisioned improvements include enhanced absorption, improved cell surface binding, and improved cell penetration. Over the intermediate term, the company intends to evaluate its technologies in the field of steroid hormones and to explore other patentable opportunities in medical therapeutics and diagnostics. Importantly, the company's technologies provide a faster, lower cost approach for chemical processes currently using the Ferrier method or other methods requiring harsh Lewis acids and high temperatures for glycosylation.
 Harrier acquired exclusive rights to the original process in 1990, and continues to sponsor its development and testing at independent research facilities. The company recently filed three patent applications covering significant additions to its technology using other sugars and an increased number of sites on the molecule where glycosylation may be more readily performed than with established methods.
 Harrier, Inc. also sells a patented healthcare device, the Bioptron(R) lamp, which is used in cosmetic skin care and for the relief of pain. A second product, the Harrier Diesel Cleaner, is a pollution control device which uses a variably controlled emulsion of fuel and water to reduce emissions produced by diesel engines in vehicles and generators.
 -0- 11/10/92
 /CONTACT: Kevin DeVito, president and CEO of Harrier, Inc., 310-376-7721/
 (HARE) CO: Harrier, Inc.; GlycoBiology Company Inc. ST: California IN: MTC SU:


TS-LR -- NY072 -- 9325 11/10/92 13:44 EST
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Nov 10, 1992
Words:357
Previous Article:WLFS/VM ENHANCES MAINFRAME'S ROLE AS FILE SERVER, SETS THE STAGE FOR DISTRIBUTED MULTIMEDIA APPLICATIONS
Next Article:SPRINT ANNOUNCES CLARITY CALL CENTER: THE FIRST PACKAGE FOR THE CALL CENTER INDUSTRY
Topics:


Related Articles
HARRIER SPONSORS PHARMACEUTICAL RESEARCH PROJECT AT U. OF MICHIGAN; ENTERS SEPARATE AGREEMENT TO FUND BIOCHEMICAL DEVELOPMENT ACTIVITY
SECOM TIES WITH HARRIER FOR JOINT R AND D OF NEW ANTI-CANCER DRUG
HARRIER/ADI MERGER NEGOTIATIONS TERMINATED
LOTUS BIOCHEMICAL RECEIVES FDA APPROVAL
Lotus Biochemical to Announce Breakthrough Drug Delivery Technology at Deutsche Banc Alex. Brown Healthcare Conference.
Lotus Biochemical to Announce Breakthrough Drug Delivery Technology at Deutsche Banc Alex. Brown Healthcare Conference.
Lotus Biochemical Corporation Opens Polypeptide Research Facility In Blacksburg, Virginia.
David S. Barlow Joins Lotus Biochemical Board of Directors.
[2] Lotus Biochemical to Announce Breakthrough Drug Delivery Technology at Deutsche Banc Alex. Brown Healthcare Conference.
Lotus Biochemical to Announce Breakthrough Drug Delivery Technology at Deutsche Banc Alex. Brown Healthcare Conference.

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters